Vernalis PLC Share News (VER)
VER Share
VER Share
VER Share
VER Share
VER
VER Share
VER Broker
VER Directors
VER Financial
VER
VER Short
VERTue, 02nd Oct 2018 15:56
LONDON (Alliance News) - Vernalis PLC on Tuesday said its acquisition by Ligand Holdings UK has been approved by shareholders.
The pharmaceutical company's shareholders passed the deal, in which Ligand will pay GBP32.7 million, or 6.2 pence per Vernalis share, with 95% of votes cast in favour.
Ligand is to fund the acquisition, which is being effected by means of a court-sanctioned scheme of arrangement, through existing cash reserves.
Shares in Vernalis were untraded at 6.12p on Tuesday.
(ShareCast News) - Vernalis has appointed 24-year AstraZeneca veteran Sandford 'Sandy' Sommer as president and chief operating officer of its US operation, Vernalis Therapeutics. Sommer most recent role was as president of AstraZeneca's Colombia operations, following a variety of leadership roles, i
Read more(ShareCast News) - Shares in Vernalis sank to an 11-month low after the biotech company posted a half-year loss as its first prescription cough cold product, Tuzistra XR, launched during what has proved a very mild flu season in the USA. Revenue was up 7% to £6.1m in the six months to 31 December, b
Read more(ShareCast News) - Pharmaceutical group Vernalis has completed the acquisition of the US rights to the amoxicillin extended-release tablet brand MOXATAG from Pragma Pharmaceuticals. The London-listed company said it has made an undisclosed up-front payment in cash for the rights, with a further paym
Read more